Skip to main content

Efficacy and Safety of Ibrutinib in Indian Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: Cases from a Named Patient Program.

Author
Abstract
:

This named patient program evaluated the safety and efficacy of ibrutinib, a selective inhibitor of Bruton's tyrosine kinase in Indian patients with relapsed/refractory chronic lymphocytic leukemia (CLL, with/without chromosome 17 deletion [del17p]) and mantle cell lymphoma (MCL).

Year of Publication
:
1969
Journal
:
Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology
Volume
:
38
Issue
:
4
Number of Pages
:
508-515
Date Published
:
1969
ISSN Number
:
0971-5851
DOI
:
10.4103/ijmpo.ijmpo_43_17
Short Title
:
Indian J Med Paediatr Oncol
Download citation